A. Thomas Bender and Allan E. Rubenstein, MD, to Retire from CooperCompanies’ Board

More Images
SAN RAMON, Calif.—CooperCompanies (NYSE:COO) announced that A. Thomas Bender and Allan E. Rubenstein, MD, have decided to retire and will not stand for re-election at the annual meeting of stockholders in March 2021. Both men have held multiple board roles spanning decades, and their guidance has been instrumental in the success of the CooperCompanies. They have helped position the company for many years of future success, according to the announcement that was made late last week.

“I want to say a huge thank you to Tom and Allan for their years of service to the company,” CooperCompanies president and chief executive officer Al White said in the announcement. “We are extremely grateful for their valuable contributions in helping shape Cooper into the fantastic company it is today.”

White added, “I’d also like to especially recognize Tom for his past CEO leadership at Cooper. He has been a driving force for Cooper, and the entire eyecare space, where he has been active for many decades. His enthusiasm, customer-centric style and passion for our business have been instrumental in creating the global, multibillion dollar company that we are today.”

Bender joined CooperVision in 1991 as president and chief operating officer. He spearheaded a comprehensive restructuring of the business, which resulted in a dramatic improvement in company performance and set the stage for a sustained period of growth, innovation, and international expansion.

In addition, Bender has served on the CooperCompanies board since 1994 and was elected chairman in July 2002. He also served as president and chief executive of CooperCompanies from May 1995 until his retirement in October 2007.

Dr. Rubenstein is retiring after 29 years of service to the company, during which he chaired multiple initiatives that enhanced both the strategic direction and clinical efficacy of the Cooper portfolio. His scientific background, combined with his focus on leveraging new technologies, has helped CooperCompanies develop a range of products that align with significant health and wellness trends.

Dr. Rubenstein has served on the CooperCompanies board as vice chairman and lead director since July 2002. He previously served as chairman of the board from July 1994 to July 2002 and acting chairman of the board from April 1993 to June 1994.

Dr. Rubenstein is a clinical professor of neurology and pediatrics at New York University Langone Medical Center. He is also medical director emeritus of the Children’s Tumor Foundation and a consultant to the National Institutes of Health, the FDA and Food and the Department of Defense.